| Study | Reason for exclusion |
|---|---|
| Bernasconi 1998 | Less than 80% MDS patients |
| Bowen 2004 | EPO and G‐CSF versus placebo |
| Bowen 2006 | EPO and G‐CSF versus placebo |
| Estey 1999 | Less than 80% MDS patients |
| Gerhartz 1994 | GM‐CSF in both arms |
| Gotlib 2009 | Not randomised |
| Greenberg 2009 | G‐CSF not randomised |
| Hast 2003 | Not MDS |
| Miller 1998 | Editorial |
| Schuster 1989 | Cross‐over design and abstract publication. Unclear, how many patients crossed‐over, no results before crossing over |
| Schuster 1995 | Cross‐over design and abstract publication. No results for each arm of the entire group published |
| Stasi 2004 | Editorial |
| Terpos 2000 | Not randomised |
| Thompson 1995 | GM‐CSF in both arms |
| Willemze 1992 | Editorial |
EPO: erythropoietin G‐CSF: granulocyte colony stimulating factors MDS: myelodysplastic syndromes